AstraZeneca's juggernaut PARP player Lynparza scoops up another dominant win in PhIII as the FDA adds a 'breakthrough' for Calquence
AstraZeneca’s oncology R&D group under José Baselga keeps churning out hits.
Wednesday morning the pharma giant and their partners at Merck parted the curtains on a successful readout for their Phase III PAOLA-1 study, demonstrating statistically significant improvement in progression-free survival for women with ovarian cancer in a first-line maintenance setting who added their PARP Lynparza to Avastin. This is their second late-stage success in ovarian cancer, which will help stave off rivals like GSK.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 67,600+ biopharma pros reading Endpoints daily — and it's free.